Patel Amends Amneal Stake Filing
Ticker: AMRX · Form: SC 13D/A · Filed: Oct 31, 2024 · CIK: 1723128
Sentiment: neutral
Topics: sec-filing, schedule-13d, ownership-update
Related Tickers: AMRX
TL;DR
Chirag Patel updated his Amneal stake filing, date of event Oct 29, 2024.
AI Summary
Chirag Patel, through an amendment filed on October 31, 2024, has updated his Schedule 13D filing regarding Amneal Pharmaceuticals, Inc. The filing indicates a change in the date of the event requiring this statement to October 29, 2024. Patel is listed with a mailing address at c/o Amneal Pharmaceuticals LLC in Bridgewater, NJ.
Why It Matters
This amendment to a Schedule 13D filing signals a potential change in significant beneficial ownership or other material information related to Amneal Pharmaceuticals, Inc., which could impact investor perception and stock movement.
Risk Assessment
Risk Level: medium — Amendments to 13D filings can indicate shifts in major shareholder positions or intentions, requiring careful monitoring.
Key Players & Entities
- Chirag Patel (person) — Filing person and beneficial owner
- Amneal Pharmaceuticals, Inc. (company) — Subject company
- 0000898432-24-000861 (filing_id) — Accession number for the filing
- October 29, 2024 (date) — Date of event requiring filing
- October 31, 2024 (date) — Filing date
FAQ
What specific changes are detailed in this Schedule 13D/A filing by Chirag Patel?
The filing is an amendment (No. 5) to a Schedule 13D and updates the 'Date of Event which Requires Filing of this Statement' to October 29, 2024.
Who is Chirag Patel in relation to Amneal Pharmaceuticals, Inc. according to this filing?
Chirag Patel is identified as the filing person and is associated with Amneal Pharmaceuticals, Inc. as the subject company.
What is the CUSIP number for Amneal Pharmaceuticals, Inc. Class A Common Stock mentioned in the filing?
The CUSIP number for Amneal Pharmaceuticals, Inc. Class A Common Stock is 03168L105.
What is the business address of Amneal Pharmaceuticals, Inc. as listed in the filing?
The business address for Amneal Pharmaceuticals, Inc. is 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807.
What is the purpose of filing a Schedule 13D/A?
A Schedule 13D/A is filed to report changes in beneficial ownership of a company's securities, requiring amendments when material changes occur.
Filing Stats: 1,331 words · 5 min read · ~4 pages · Grade level 12.7 · Accepted 2024-10-31 18:51:29
Key Financial Figures
- $0.01 — ssuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L
- $15.01 — pon exercise of options exercisable for $15.01 per share, which expire on May 7, 2028
- $14.05 — pon exercise of options exercisable for $14.05 per share, which expire on May 6, 2029;
Filing Documents
- sc13d-a.htm (SC 13D/A) — 63KB
- exh99-5.htm (EX-99.5) — 143KB
- exh99-6.htm (EX-99.6) — 64KB
- image0.jpg (GRAPHIC) — 363KB
- image1.jpg (GRAPHIC) — 2KB
- image00006.jpg (GRAPHIC) — 46KB
- image00007.jpg (GRAPHIC) — 146KB
- image00012.jpg (GRAPHIC) — 151KB
- image00013.jpg (GRAPHIC) — 27KB
- image00014.jpg (GRAPHIC) — 63KB
- image00015.jpg (GRAPHIC) — 47KB
- 0000898432-24-000861.txt ( ) — 1437KB
of the Schedule 13D is hereby amended and supplemented by adding the following information
Item 6 of the Schedule 13D is hereby amended and supplemented by adding the following information. On October 29, 2024, the Reporting Person and his spouse, as well as certain trusts controlled by the Reporting Person and his spouse (collectively, the "Borrowers"), entered into a Third Amended and Restated Margin Loan Agreement (the "Margin Loan Agreement") with UBS AG Stamford Branch, as successor by merger to Credit Suisse AG ("UBS"). In connection therewith, the Borrowers agreed to pledge to UBS 17,000,000 shares of Class A Common Stock (the "Collateral") to secure the obligations of the Borrowers under the Margin Loan Agreement. The obligations of the Borrowers under the Margin Loan Agreement mature on October 29, 2026. Upon the occurrence of certain events that are customary with this type of transaction, UBS may exercise its rights to foreclose on, and dispose of, the Collateral in accordance with the Margin Loan Agreement. In order to facilitate the exercise by UBS of its rights upon the occurrence of any such event, each of the Borrowers also entered into (i) an Account Control Agreement, dated as of October 29, 2024, by and among the Borrowers, UBS, and UBS Financial Services Inc. and (ii) a Letter Agreement, dated as of October 29, 2024, by and among the Borrowers, UBS and the New Issuer (together, the "Collateral Agreements"). Copies of the forms of Collateral Agreements are attached as Exhibits to this Schedule 13D, and are incorporated herein by reference. The foregoing arrangement amended and restated the Promissory Note and Collateral Agreement and related Collateral Agreements previously disclosed in Amendment No. 2 to the Schedule 13D, which agreements are no longer effective. Except as set forth herein, the Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understand
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : October 31, 2024 /s/ Chirag Patel Chirag Patel